Posted on 01/03/2024 10:19:33 AM PST by george76
Harvard University’s Provost and Interim President Dr. Alan Garber has made millions from sitting on pharmaceutical company boards during his time with the school.
Garber made more than $2.7 million from board seats with pharmaceutical firms Exelixis, Inc. and Vertex Pharmaceuticals since becoming Harvard provost in 2011, the Harvard Crimson reported in 2019, citing company filings with the Securities and Exchange Commission (SEC).
Both firms confirmed to the outlet Garber received compensation without performing any additional duties beyond his board memberships.
...
He joined Exelixis’ board in 2005 and received $2.3 million from the company, $1.6 of which came after he joined Harvard as provost and chief academic officer in 2011. From 2017-18, Garber made around $1.2 million from Vertex in the form of cash and stock options.
“The insights he has developed as an expert in health care policy and as an advisor to government agencies will provide our board important perspectives on the issues facing our company,” Vertex said of Garber at its June 2017 annual meeting, according to the Crimson.
Garber continues to sit on the Exelixis and Vertex corporate boards. The companies did not immediately respond to requests for comment.
Vertex’s market capitalization is roughly $105 billion and specializes in developing treatments for serious diseases such as Cystic Fibrosis, its website shows. Exelixis has a roughly $7 billion market capitalization and focuses on developing next generation cancer treatments, according to its website.
At Harvard, Garber supervises academics, faculty and research, international affairs and learning advances, according to his official bio. Garber is an economist and physician with professorships at Harvard’s medical school, public health school, arts and sciences faculty and Kennedy School of Government in addition to his provost role.
...
He was previously an economics and medicine professor at Stanford, where he earned his MD in 1983. He also received an economics PhD from Harvard after receiving his undergraduate degree from Harvard in 1976. His research focuses on improving healthcare delivery, particularly for elderly in situations where resources are limited.
He is assuming the role of Harvard’s interim president after former Harvard President Claudine Gay resigned Tuesday following numerous plagiarism accusations.
Gay attributed her resignation to “racial animus” and did not offer an apology for her alleged plagiarism throughout her academic career.
SSDD.
Self-dealing = “Science”.
Follow the science er money.
Just like Fauci the criminal.
Claudine Gay is an embarrassment for Harvard and an indictment of most American colleges.
Isolate the medical school and burn the rest to ashes.
Dr. Garber has memorized an impressive list of cliches, but stringing them together, as though they contained substance, is nauseating.
[snip] Alan Garber, the school’s provost, as interim president... sat behind Gay during her congressional testimony, nodding in agreement as she gave her remarks. [/snip]
https://freerepublic.com/focus/news/4207501/posts=
Bring lots of matches cuz this happens everywhere all the time. It’s why we’re screwed.
Nothing to see here. It’s just more poison ivy to cover the walls at the Ivy League schools.
It’s not a school of “higher learning”. It’s a leftard factory.
The moral fiber of the US has become breath taking.
Harvard scum can ride the reputations of people who came before them... but that only last for so long.
It has lasted at least 50 years. American parents have to finish it off.
Class of ‘76?
That appears to be the case. I was confused because at that time he was enrolled at both harvard and stanford. He might have bachelor's from both. He seems to be more qualified by far than Gay but has the wrong skin color.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.